Use of luteinizing hormone-releasing hormone analogs in the treatment of hormone-dependent tumors

Andrew V Schally, A. M. Comaru-Schally

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Therapeutic regimens based on the use of LHRH analogs and somatostatin analogs might supplement, or in some cases replace, conventional procedures for the treatment of hormone-sensitive cancers. Experimental studies showed that agonists of LHRH might be useful for treatment of androgen-dependent prostate cancer and estrogen-dependent breast cancer. Clinical results accumulated during the past few years support this view. On the basis of experimental findings, LHRH agonists could also be considered as adjuncts for therapy of chondrosarcomas, osteosarcomas, and pancreatic cancer, but the principal approach for the treatment of these neoplasms might be based on somatostatin analogs. In turn, somatostatin analogs could serve as adjuncts in treatment of prostate cancer and breast cancer. Long-acting delivery systems for once-a-month administration of microcapsules of D-Trp6 LHRH have been successfully combined with some chemotherapeutic agents such as Cytoxan and Novantrone in the experimental treatment of prostate cancer. Work is in progress on the use of LHRH analogs for the treatment of ovarian cancer and neoplasms of the female genital tract.

Original languageEnglish
Pages (from-to)389-398
Number of pages10
JournalSeminars in Reproductive Endocrinology
Volume5
Issue number4
StatePublished - Dec 1 1987
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Hormones
Somatostatin
Prostatic Neoplasms
Neoplasms
Breast Neoplasms
Ovarian Neoplasms
Mitoxantrone
Chondrosarcoma
Osteosarcoma
Pancreatic Neoplasms
Cyclophosphamide
Androgens
Capsules
Estrogens
Therapeutics

ASJC Scopus subject areas

  • Endocrinology
  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Reproductive Medicine

Cite this

Use of luteinizing hormone-releasing hormone analogs in the treatment of hormone-dependent tumors. / Schally, Andrew V; Comaru-Schally, A. M.

In: Seminars in Reproductive Endocrinology, Vol. 5, No. 4, 01.12.1987, p. 389-398.

Research output: Contribution to journalArticle

@article{efda69d22bcc4a71a439a7063d451c3d,
title = "Use of luteinizing hormone-releasing hormone analogs in the treatment of hormone-dependent tumors",
abstract = "Therapeutic regimens based on the use of LHRH analogs and somatostatin analogs might supplement, or in some cases replace, conventional procedures for the treatment of hormone-sensitive cancers. Experimental studies showed that agonists of LHRH might be useful for treatment of androgen-dependent prostate cancer and estrogen-dependent breast cancer. Clinical results accumulated during the past few years support this view. On the basis of experimental findings, LHRH agonists could also be considered as adjuncts for therapy of chondrosarcomas, osteosarcomas, and pancreatic cancer, but the principal approach for the treatment of these neoplasms might be based on somatostatin analogs. In turn, somatostatin analogs could serve as adjuncts in treatment of prostate cancer and breast cancer. Long-acting delivery systems for once-a-month administration of microcapsules of D-Trp6 LHRH have been successfully combined with some chemotherapeutic agents such as Cytoxan and Novantrone in the experimental treatment of prostate cancer. Work is in progress on the use of LHRH analogs for the treatment of ovarian cancer and neoplasms of the female genital tract.",
author = "Schally, {Andrew V} and Comaru-Schally, {A. M.}",
year = "1987",
month = "12",
day = "1",
language = "English",
volume = "5",
pages = "389--398",
journal = "Seminars in Reproductive Medicine",
issn = "1526-8004",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Use of luteinizing hormone-releasing hormone analogs in the treatment of hormone-dependent tumors

AU - Schally, Andrew V

AU - Comaru-Schally, A. M.

PY - 1987/12/1

Y1 - 1987/12/1

N2 - Therapeutic regimens based on the use of LHRH analogs and somatostatin analogs might supplement, or in some cases replace, conventional procedures for the treatment of hormone-sensitive cancers. Experimental studies showed that agonists of LHRH might be useful for treatment of androgen-dependent prostate cancer and estrogen-dependent breast cancer. Clinical results accumulated during the past few years support this view. On the basis of experimental findings, LHRH agonists could also be considered as adjuncts for therapy of chondrosarcomas, osteosarcomas, and pancreatic cancer, but the principal approach for the treatment of these neoplasms might be based on somatostatin analogs. In turn, somatostatin analogs could serve as adjuncts in treatment of prostate cancer and breast cancer. Long-acting delivery systems for once-a-month administration of microcapsules of D-Trp6 LHRH have been successfully combined with some chemotherapeutic agents such as Cytoxan and Novantrone in the experimental treatment of prostate cancer. Work is in progress on the use of LHRH analogs for the treatment of ovarian cancer and neoplasms of the female genital tract.

AB - Therapeutic regimens based on the use of LHRH analogs and somatostatin analogs might supplement, or in some cases replace, conventional procedures for the treatment of hormone-sensitive cancers. Experimental studies showed that agonists of LHRH might be useful for treatment of androgen-dependent prostate cancer and estrogen-dependent breast cancer. Clinical results accumulated during the past few years support this view. On the basis of experimental findings, LHRH agonists could also be considered as adjuncts for therapy of chondrosarcomas, osteosarcomas, and pancreatic cancer, but the principal approach for the treatment of these neoplasms might be based on somatostatin analogs. In turn, somatostatin analogs could serve as adjuncts in treatment of prostate cancer and breast cancer. Long-acting delivery systems for once-a-month administration of microcapsules of D-Trp6 LHRH have been successfully combined with some chemotherapeutic agents such as Cytoxan and Novantrone in the experimental treatment of prostate cancer. Work is in progress on the use of LHRH analogs for the treatment of ovarian cancer and neoplasms of the female genital tract.

UR - http://www.scopus.com/inward/record.url?scp=0023520121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023520121&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023520121

VL - 5

SP - 389

EP - 398

JO - Seminars in Reproductive Medicine

JF - Seminars in Reproductive Medicine

SN - 1526-8004

IS - 4

ER -